Get up to 2 Years of free subscription by inviting your friends to KALKINE!

For every friend of yours who joins KALKINE, we'll give you 3 months of free subscription (up to a limit of 24 months free subscription). If you recommend 3 friends and they join within a month of you referring them, you get 1 year free subscription to KALKINE reports added to your account (up to a limit of 24 months free subscription). Simply reply to this email with their name, e-mail and phone number.
 

Upcoming IPO's Video


 

Snapshot of the upcoming IPO's

Skydive the Beach Group Limited is a skydiving company having about 11 existing drop zones across Australia. The Company also seems to acquire another five drop zones on Australia’s East Coast. Through the Initial Public Offer (IPO), the Company expects to raise about $20 million of capital (ASX proposed code: SKB). The Company lodged a Replacement Prospectus with the Australian Securities and Investments Commission replacing the original prospectus dated and lodged on 19 February 2015. The offer extends up to 80,000,000 fully paid shares for $0.25 per share with the ability to raise a further $5,000,000 in oversubscriptions. Normal trading of Shares on ASX is expected around 30 March 2015. The Company expects to use the offer proceeds for funding the proposed acquisition of Australia Skydive and to retire some debt among other requirements. A dividend with respect to FY15 ending 30 June 2015 of $0.01 per share is expected to be payable to shareholders in October 2015 subject to certain conditions.



Skydive the Beach Group Limited_Financials (Source – Company Reports)

ALT Resources Limited (ASX proposed code: ARS), known to be an Australian based mineral exploration entity, incorporated in April 2014 and set to acquire up to 70% interest in tenements held by GFM Exploration Pty Ltd, is looking forward to raise a capital for exploration of about $4 million. GFM is the registered holder of three tenements in the south-east Lachlan Orogen in New South Wales. The Company lodged its prospectus for inviting applications for shares on or around 5 February 2015. The IPO, led by Novus Capital, is supposed to have the listing dates later the present quarter or sometime early 2Q 2015. The Company has even extended the closing date of the offer to 15 May 2015. This IPO may open-up the opportunity in an early stage base and metal company for many investors. Operational drilling programs planned for the current year can be striking points. The Paupong Project, which is a new greenfields discovery by GFM exploration, illustrates a major gold bearing quartz-sulphide vein system extending over an area of 25 square km at the surface. This project is drill ready and is supported by the approval granted by the NSW Department Trade and Industry Resources and Energy for about 100 Reverse Circulation and Diamond Core holes. Another project, the Myalla Prospect (EL 8164), situated 30 km from the Paupong Project covering 54 square km has shown good prospects with gold bearing sulphide mineralization and the possibility of a near surface monzogranite in the south-west of the tenement.


Alt Resources Prospects (Source – Company Reports)

Proteomics International Laboratories Ltd provides solutions in the domain of biological research and drug discovery with simple diagnostic tests for common diseases. The Company is also engaged in discovering new therapeutic drugs. The Company recently announced for the finalization of an agreement with regards to a deal potentially worth $312m annually with New Summit Biopharma (Chinese bio-pharmaceutical company) to commercialise its diabetic kidney diagnostic in China. This is reported to be the first-ever proteomics derived In-Vitro Diagnostic for Chinese market. The Company aims to provide investors with pioneering exposure to the proteomics field through extensive research and development. The Company is known to be world’s first ISO proteomics laboratory accreditation for its Perth facility in 2009. Through the IPO, the Company aimed to float 30m shares on offer at a listing price of $0.20 and market capitalization is expected to be of the order of $13.1 million (ASX proposed code: PIQ). The shares will commence trading on the ASX in March/April 2015. The benefits from the listing will be directed towards R&D activities supplemented by cashflow from contract research operations. There is a good indication by the Company that the major growth opportunity for new investors circumscribes around Proteomics’ intellectual property portfolio with its key asset entailing a patent-pending diagnostics test for diabetic kidney disease expected to be commercialised through a licensing agreement within 12 months. The recent launch of the unique test called “2tag” (patent-protected) for oxidative stress is also an important landmark development.



Another such entity is Genetic Signatures Limited, the developer of 3base™ technology, which has also been known for the development and commercialization of EasyScreen™ Real-Time PCR based kits for routine detection of infectious diseases. This area proffers immense potential with regards to the molecular tools required by hospitals and pathology laboratories for screening a wide array of infectious pathogens in a rapid and high-throughput environment.


Genetic Signatures Financials (Source – Company Reports)


The Company has highlighted that its customer base primarily constitutes large hospital and pathology laboratories in Australia, however, the target base includes markets in the US and the EU as the Company’s products have been developed to meet existing and planned future requirements in said markets as well. Through the IPO, the Company expected to raise capital of about $15 million. The Company has recently announced about successful closing of the IPO at the maximum raising of 7.5 million. It has further informed that it expects the listing of shares, which are to be issued at $0.40 per share, on the ASX on 31 March 2015 (ASX proposed code: GSS).